Trial Profile
Clinical Trials Insight: 700029950
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Jun 2008
Price :
$35
*
At a glance
- Drugs Renzapride (Primary)
- Indications Irritable bowel syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Alizyme
- 06 Mar 2008 Recruitment is expected to commence following conclusion of a commercial deal, according to a Alizyme media release.
- 18 Jan 2008 New trial record.